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PURPOSE. We tested the potential of bone morphogenic protein 7 (BMP7) and hepatocyte
growth factor (HGF) combination gene therapy to treat preformed corneal fibrosis using
established rabbit in vivo and human in vitro models.
METHODS. Eighteen New Zealand White rabbits were used. Corneal fibrosis was produced by
alkali injury. Twenty-four hours after scar formation, cornea received topically either balanced
salt solution (BSS; n ¼ 6), polyethylenimine-conjugated gold nanoparticle (PEI2-GNP)-naked
plasmid (n ¼ 6) or PEI2-GNP plasmids expressing BMP7 and HGF genes (n ¼ 6). Donor
human corneas were used to obtain primary human corneal fibroblasts and myofibroblasts for
mechanistic studies. Gene therapy effects on corneal fibrosis and ocular safety were evaluated
by slit-lamp microscope, stereo microscopes, quantitative real-time PCR, immunofluorescence, TUNEL, modified MacDonald-Shadduck scoring system, and Draize tests.
RESULTS. PEI2-GNP–mediated BMP7þHGF gene therapy significantly decreased corneal
fibrosis in live rabbits in vivo (Fantes scale was 0.6 in BMP7þHGF-treated eyes compared to
3.3 in therapy group; P < 0.001). Corneas that received BMP7þHGF demonstrated
significantly reduced mRNA levels of profibrotic genes: a-SMA (3.2-fold; P < 0.01), fibronectin
(2.3-fold, P < 0.01), collagen I (2.1-fold, P < 0.01), collagen III (1.6-fold, P < 0.01), and
collagen IV (1.9-fold, P < 0.01) compared to the therapy corneas. Furthermore,
BMP7þHGF-treated corneas showed significantly fewer myofibroblasts compared to the
therapy controls (83%; P < 0.001). The PEI2-GNP introduced >104 gene copies per
microgram DNA of BMP7 and HGF genes. The recombinant HGF rendered apoptosis in
corneal myofibroblasts but not in fibroblasts. Localized topical BMP7þHGF therapy showed
no ocular toxicity.
CONCLUSIONS. Localized topical BMP7þHGF gene therapy treats corneal fibrosis and restores
transparency in vivo mitigating excessive healing and rendering selective apoptosis in
myofibroblasts.
Keywords: HGF, BMP7, PEI-GNP, gene therapy, corneal fibrosis

njuries and infections of the eye compromise corneal
transparency, which accounts for two-thirds of the eye’s
refraction and results in vision loss in an estimated 1.3 million
Americans annually. Worldwide, corneal disorders are the third
leading cause of preventable blindness.1,2 Despite increasing
knowledge about the molecular mechanisms underlying
corneal scarring,3 currently available therapies4 rely primarily
on steroids and other drugs that carry the risk of multiple side
effects,5 require repeated applications, and are often ineffective
in restoring vision completely. Although mitomycin C (MMC) is
a commonly used topical treatment for corneal fibrosis,6 its use
continues to be the subject of debate due to its long-term side
effects.7 A limbal graft is the treatment of choice in countries
where donor corneal limbus is available.8 Corneal transplanta-

I

tion remains the gold standard for the treatment of corneal
scars and restoration of vision.9 In 2015 alone, 48,792 corneal
transplantations were performed in the United States, according to the Eye Bank Association of America (http://restoresight.
org/wp-content/uploads/2016/03/2015-Statistical-Report.pdf),
and about 12.7 million people in the world are awaiting donor
corneal tissues.10 Besides the limited availability of donor
corneas, a high immunologic rejection rate is another limiting
factor for restoring vision from corneal transplantation. Thus,
there is an undisputable need for the development of effective
and safe nonsurgical targeted treatments for corneal fibrosis,
including gene-based therapies that would provide long-term
effectiveness, require minimal clinical follow up, and show
minimal side effects.
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BMP7þHGF Gene Therapy for Corneal Fibrosis
Studies show that injury and infection to the cornea/eye
leads to the activation of quiescent stromal keratocytes in the
cornea, which then migrate to the wound site and transdifferentiate to a wound-repair phenotype, referred to as
myofibroblasts.4 While molecular signaling and secretory
functions of myofibroblasts are essential for proper corneal
wound repair, their continued production and prolonged
presence in the stroma lead to corneal fibrosis (haze or
scarring) due to the extended activity of TGF-b signaling during
corneal wound repair.11 The activation and differentiation of
keratocytes have been shown to occur as a response to IL-1a/
IL-1b, which are released by corneal epithelial cells after
injury.12 In addition, multiple molecules, factors, ligands, and
cytokines, including TGF-b released from injured epithelial
cells, play a pivotal role in the induction of inflammation and
corneal scarring due to excessive biological activities and
fusion of extracellular matrix (ECM) and cytoskeletal proteins.3,4 TGF-b signaling is largely responsible for the transdifferentiation of keratocytes into myofibroblasts. The
persistence of myofibroblasts after wound healing is known
to be a major factor in the pathogenesis of corneal fibrosis and
opacity, and ultimately, vision impairment.3,13
The TGF-b superfamily proteins activate downstream
signaling via the Smad family of proteins.14 Bone morphogenic
protein (BMP) belongs to the TGF-b superfamily and plays a
significant role in ECM synthesis, tissue repair, and remodeling
processes during corneal wound healing.15 The signaling
protein BMP7 was originally described to have a significant
role in the development of mammalian organs such as the
kidney and the eye.16 BMP7 binds to the type I and II receptors
and regulates receptor-regulated Smads (Smad1, Smad5, and
Smad8) and inhibitory Smads (Smad6 and Smad7) in a complex
wound-healing signaling network.17 In addition to BMP7, the
expression of hepatocyte growth factor (HGF) and its receptor
proteins has been found in the cornea, lacrimal glands, and
tears.18,19 HGF has been identified as a mitogen that functions
through the c-Met receptor tyrosine kinase in the protection
and regeneration of organs20 as well as in the modulation of
corneal repair.21,22 Injury to corneal epithelium has been
shown to upregulate HGF expression in keratocytes, and in
addition to its intracrine and autocrine functions, HGF has
been shown to function in a paracrine manner in modulating
corneal wound healing.23 The role of HGF and the c-Met
system in diabetic corneal wound healing was recently well
established in organotypic human diabetic corneal cultures.4
Furthermore, HGF has been reported to have a role in the
breakdown of ECM deposits and in the reduction of fibrosis in
several nonocular tissues.24 Despite the important role of HGF
in corneal wound healing and TGF-b profibrotic signaling,
mechanistic knowledge about the crosstalk between HGF and
BMP7 in the cornea remains unknown, especially during
wound healing and profibrotic microenvironment.
The cornea represents a perfect tissue for gene therapy
because of its well-defined characteristics such as transparency, simple anatomy, and ease of access, allowing topical
instillation of gene delivery vectors and visual monitoring of
the genes packaged within vectors.25 In addition, therapeutic
response can also be assessed noninvasively with highresolution ocular imaging using stereo and slit-lamp biomicroscopy.26 Our group previously reported the advantages of
tissue-specific gene delivery using a variety of modalities,
including direct instillation of hybrid nanoparticle or adenoassociated virus vectors.17,27,28 We found that nonviral gene
delivery systems based on synthetic polycations,29–31 such as
polyethylene amine (PEI), show promise as delivery systems
for gene therapy. They possess DNA-binding capabilities,
provide options for functionalization, and show a good safety
profile. In subsequent studies, we greatly enhanced the

otherwise low transfection efficiency of PEI (2 kDa) by
conjugating PEI with gold nanoparticles to synthesize PEIconjugated gold nanoparticles (PEI2-GNP).32 Utilizing these
hybrid gold nanoparticles, we established a novel nanoparticle-based gene delivery system for the cornea that demonstrates efficient gene transfer into rabbit corneal stroma in
vivo with negligible toxicity.17,29
BMP7 and HGF are attractive targets for modulating the
profibrotic signaling pathways in corneal wound healing. Our
previous study of BMP7 gene therapy by PEI2-GNP in the
preclinical rabbit model of corneal fibrosis revealed that PEI2GNP–based BMP7 gene therapy led to significant inhibition of
corneal fibrosis and corneal repair through counterbalancing
the deleterious effects of TGF-b–induced Smad signaling.17
HGF gene therapy has been shown by other investigators to
regulate fibrosis in various nonocular tissues, including the
liver,20 lung,33 and kidney.34 Phase-I and phase-II clinical trials
indicate HGF gene therapy is safe in humans.35,36 Furthermore, HGF gene transfer has been found to cause selective
apoptosis of myofibroblasts in nonocular tissues.37–39 These
reports led to an innovative postulate that PEI2-GNP–
mediated tissue-targeted localized BMP7þHGF gene therapy
in rabbit cornea would effectively eliminate preexisting
fibrosis in vivo without producing significant toxicity. The
present study tested the therapeutic potential of PEI2-GNP–
delivered BMP7þHGF gene therapy for abolishing preexisting
corneal fibrosis in vivo using a well-established preclinical
rabbit model of corneal fibrosis.

MATERIALS

AND

METHODS

Corneal Fibrosis Induction and Treatment in
Rabbits
Eighteen New Zealand White female rabbits, weighing 2 to 3
kg (Covance Research Products, Denver, PA, USA) were used in
the study. Institutional approval of the study was obtained from
the Harry S. Truman Memorial Veterans’ Hospital and the
Institutional Animal Care and Use Committee of the University
of Missouri (both in Columbia, MO, USA). All animals were
treated in accordance with the principles of the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. The rabbits were anesthetized by a mixture of
ketamine hydrochloride (50 mg/kg) and xylazine hydrochloride (10 mg/kg), given intramuscularly, for induction of corneal
alkali-induced wounding, for administration of PEI2-GNP–
mediated BMP7þHGF gene delivery to the corneal stroma,
and for the performance of clinical slit-lamp eye examinations
and ocular stereo biomicroscopy. Topical ophthalmic proparacaine hydrochloride (0.5%; Alcon, Fort Worth, TX, USA) was
administered for local anesthesia prior to all procedures.

IOP Monitoring by Tonometry
Variations in IOP, an indicator of an ocular abnormality, may
result from inflammation, swelling, rigidity, abrasion, and
irregularities in corneal tissues. Administration of therapeutic
genes into stroma has potential for alterations in the aqueous
humor or in tissues of the anterior chamber, which is a
significant concern after gene therapy. Thus, IOP measurements in rabbit eyes were recorded using a tonometer (TonoPen AVIA; Reichert Technologies, Depew, NY, USA) at regular
timed intervals on days 1, 7, 14, and 21 and before each clinical
biomicroscopy evaluation as reported earlier.40 All IOP
measurements were performed between 9 AM and 11 AM to
minimize normal diurnal variations in IOP.

BMP7þHGF Gene Therapy for Corneal Fibrosis

In Vivo Alkali-Induced Corneal Scarring
Corneal scarring was induced in one eye of each rabbit, and
the contralateral eye served as a naive control. To induce
corneal scarring, rabbits were anesthetized and an 8-mm filter
paper soaked in 0.5 N sodium hydroxide solution was applied
onto the central cornea for 1.0 minutes under visualization
with the surgical microscope (Leica Wild Microscope MEL53;
Leica, Wetzlar, Germany). The wounded corneas were immediately and copiously rinsed with sterile balanced salt solution
(BSS) to remove alkali residual. This method triggered wound
healing and produced dense corneal scarring and peak fibrosis
at 3 weeks with minimal neovascularization.41

PEI2-GNP Transfection Solution
Thiol-modified PEI2-GNPs were synthesized as described
earlier.32 The PEI2-GNP transfection solution was prepared as
reported previously.17 In brief, the PEI2-GNPs were mixed with
plasmid at a nitrogen-to-phosphate (N/P) ratio of 180 by
stirring 37.5 lL of 150 mM PEI2-GNPs with 10 lg plasmid DNA
(pTRUF11 expressing HGF or BMP7 under control of hybrid
cytomegalovirus [CMV] chicken b-actin promoter), 10%
glucose (wt/vol), and bringing the volume to 100 lL with
BSS. The solution was incubated at 378C for 30 minutes prior
to application on the cornea.

In Vivo Gene Delivery
One eye of each animal was treated and the contralateral eye
served as naive control. To determine the effectiveness of gene
therapy for preexisting corneal fibrosis, PEI2-GNP–mediated
BMP7þHGF gene therapy was delivered into rabbit stroma 24
hours after alkali injury. BSS or transfection solution was
topically applied to the cornea for 5 minutes using a cloning
cylinder, as previously reported.17,29 The rabbits were divided
into three groups: group 1 rabbits received BSS alone (n ¼ 6; no
gene transfer naive group); group 2 rabbits received PEI2-GNPnaked plasmid without BMP7 or HGF gene (n ¼ 6; therapy
group); and group 3 rabbits (n ¼ 6) received PEI2-GNP
plasmids expressing HGF and BMP7 genes (n ¼ 6; þtherapy
group). The cloning cylinder method is known to deliver
significant levels of therapeutic genes into rabbit stroma in vivo
with low toxicity.17,29

Slit-Lamp Biomicroscopy, Haze Quantification,
and Fluorescein Eye Test
Corneal defects and general ocular health were documented at
baseline and after alkali wounding at various time points using
a handheld slit-lamp microscope equipped with a digitalimaging system (SL-15; Kowa Optimed, Torrance, CA, USA).
Using the Fantes scale, the intensity of corneal haze was graded
by three independent observers (SG, AS, MK) masked to the
treatment group, as reported earlier.28,42 In brief, the grading
system was the following: grade 0, completely clear cornea;
grade 0.5, trace haze seen with careful oblique illumination;
grade 1, more obvious haze but not interfering the visualization
of fine iris details; grade 2, mild obscuration of iris details;
grade 3, moderate obscuration of the iris and lens; and grade 4,
complete opacification of the stroma in the area of ablation.
Fluorescein sodium sterile ophthalmic strips (0.6 mg, FulGlo; Akorn, Lake Forest, IL, USA) were used to evaluate the
health of the corneal epithelium and tear production. In brief, a
BSS-moistened fluorescein strip was applied to the dorsal
upper eyelid of rabbits, and the rabbits were allowed to blink
for distributing fluorescein stain over the entire corneal and
conjunctival surface. After 30 seconds, corneal epithelium was

IOVS j February 2018 j Vol. 59 j No. 2 j 1047
observed under blue light using wide and narrow beams of the
slit-lamp microscope. Images were obtained with a stereo
microscope fitted with a fluorescence filter, spot camera, and
imaging software. Tear levels were measured using commercial
diagnostic strips (Tear-Flow Diagnostic Strips; HUB Pharmaceuticals, Rancho Cucamonga, CA, USA).

Ocular Irritation Tests
The ocular health and anomalies were evaluated independently
at selected times by at least two of three examiners (MF, AS,
and SG) using the established Draize43 and modified MacDonald-Shadduck44 ocular scoring systems. With the Draize eye
test, the severity of ocular lesions was scored in the following
manner: in the cornea, by estimating the degree of opacity and
area of involvement; in the iris, by examining pupillary light
reflexes; and in the conjunctiva, by assessing the degree of
redness, chemosis, and discharge. With the modified MacDonald-Shadduck scoring system, ocular health scores were
determined based on the cumulative average scores for corneal
tissue (opacity, affected area, corneal neovascularization
severity, and reepithelization) and for conjunctival tissue
(congestion, chemosis, swelling, and discharge).

Euthanasia and Tissue Collection
Rabbits were humanely euthanized with pentobarbital (150
mg/kg) while they were under general anesthesia. Corneas
were harvested, immediately placed in 15 3 5 3 5-mm molds
(Fisher Scientific, Pittsburgh, PA, USA) containing optical
cutting temperature (OCT) compound, and snap frozen by
immersion in a cryo-cup containing 2-methylbutane sitting in
liquid nitrogen. Frozen tissue blocks were preserved at 808C.
The corneas were cut in two equal halves; one half was used
for histologic studies, and other half was used for molecular
studies. For histologic studies, serial corneal sections (8 lm)
were prepared with a cryostat (HM525 NX UV; Microm GmbH,
Walldorf, Germany), placed on glass microscopic slides
(Superfrost Plus; Fisher Scientific, Pittsburgh, PA, USA), and
kept at 808C until analysis. For molecular studies, corneas
were cut into small pieces, immediately immersed in a cryocup placed in liquid nitrogen, and subsequently ground and
processed for obtaining genomic DNA, mRNA, and cDNA
following vendor’s protocols (Qiagen, Germantown, MD, USA).

Hematoxylin and Eosin, Masson’s Trichome,
Immunofluorescence and TUNEL Staining
Hematoxylin-eosin (H&E) and Masson’s trichome staining were
performed using the standard procedure for visualizing
morphologic details, as reported earlier.40,45 Immunofluorescence staining was performed following reported methods17 to
measure myofibroblasts in the corneas using antibody-specific
a-smooth muscle actin (a-SMA), a marker for myofibroblasts.
Briefly, corneal sections were blocked with 2% bovine serum
albumin at room temperature for 30 minutes, followed by
incubation with a-SMA mouse monoclonal primary antibody
(1:200 dilution, M0851; Dako, Carpentaria, CA, USA) for 90
minutes and then incubated with Alexa-Fluor 488 goat antimouse IgG secondary antibody (1:1000 dilution, A11001;
Invitrogen, Carlsbad, CA, USA) for 1 hour at room temperature.
Appropriate positive and negative controls were included in
each immunostaining. Quantification of a-SMA-positive cells
was performed in six randomly selected, nonoverlapping, fullthickness central corneal columns, extending from the anterior
stromal surface to the posterior stromal surface at 2003 and
4003 magnification fields.
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The toxicity of PEI2-GNPs and BMP7þHGF gene therapy
was determined by performing a TUNEL assay (ApopTag;
Millipore, Temecula, CA, USA). Corneal sections were fixed in
acetone at –208C for 10 minutes, and a TUNEL assay was
performed per the manufacturer’s instructions, including
suitable positive and negative controls. Rhodamine-conjugated apoptotic cells (red) and 4 0 ,6-diamidine-2 0 -phenylindole
dihydrochloride (DAPI)–stained nuclei (blue) were viewed
and photographed with a fluorescence microscope (Leica)
fitted with a digital camera system (SpotCamRT KE; Diagnostic Instruments, Sterling Heights, MI, USA). DAPI-stained
nuclei and TUNEL-positive cells in untreated and treated
tissues were quantified at 2003 and 4003 magnification in six
randomly selected nonoverlapping areas, as previously
reported.17,28

RNA Extraction, cDNA Synthesis, and Quantitative
Real-Time PCR
Total RNA from tissues was extracted with an RNeasy kit
(Qiagen, Valencia, CA, USA) and reverse transcribed to cDNA
following reported methods.17,28 Real-time PCR was performed using the StepOne Plus PCR system (Applied
Biosystems, Carlsbad, CA, USA). A 20-lL reaction mixture
contained 2 lL cDNA, 2 lL forward and reverse primers (200
nM each), and 10 lL 2X All-in-One quantitative PCR (qPCR)
mix (GeneCopoeia, Rockville, MD, USA) and was run at a
universal cycle (958C for 10 minutes, 40 cycles at 958C for 15
seconds, and 608C for 60 seconds), as previously reported.16
The primer sequences of genes were the following: a-SMA—
forward TGG GTG ACG AAG CAC AGA GC and reverse CTT
CAG GGG CAA CAC GAA GC; fibronectin—forward CGC
AGC TTC GAG ATC GTG C and reverse TCG ACG GGA TCA
CAC TTC CA; collagen type I—forward TGT GGC CCA GAA
CTG GTA CAT and reverse ACT GGA ATC CAT CGG TCA TGC
TCT; collagen type III—forward AGA ACA CGC AAG GCT
GTG AGA CTA and reverse CCA ACG TCC GCA CCA AAT TCT
TGA; collagen type IV—forward TAT CGA ACA ACG CAA
GGC TGT GAG A and reverse GGC CAA CGT CCA CAC CAA
ATT CTT; and b-actin—forward CGG CTA CAG CTT CAC CA
and reverse CGG GCA GCT CGT AGC TCT TC. The b-actin
was used for the normalization of qPCR data, and showed no
appreciable relative fold change at various tested points and
groups.

Quantification of Nanoparticle-Delivered Gene
Copies
The frozen corneal tissues were pulverized in liquid
nitrogen, and genomic DNA was isolated (DNA Easy kit;
Qiagen, Valencia, CA, USA). Quantitative PCR was performed
to determine PEI2-GNP–delivered gene copies of HGF and
BMP7 in corneal tissues.17 A 10-fold serial dilution of
plasmid having test gene (104–109/mg DNA) was used for
standard curves. The qPCR settings were 958C for 10
minutes, 40 cycles at 958C for 15 seconds, and 608C for 60
seconds.

Human Corneal Fibroblast and Myofibroblast
Cultures
Primary human corneal fibroblast (HCF) cultures were
generated from donor human corneas purchased from an
eye bank (Saving Sight, Kansas City, MO, USA) following
methods described previously.30 The corneal epithelium and
endothelium were removed from corneal buttons with a
surgical blade and cut into small pieces, placed on culture

dishes, and incubated for 3 to 5 weeks in a humidified CO2
(5%) incubator at 378C in MEM supplemented with 10% fetal
bovine serum. Seventy percent confluent HCF cultures that
underwent fewer than four passages were used in the
experiments. Human corneal myofibroblasts were produced
by culturing HCFs under serum-free conditions in the
presence of TGF-b1 (PeproTech, Rocky Hill, NJ, USA), 5 ng/
mL for 72 hours.

Lactate Dehydrogenase Assay
Lactate dehydrogenase (LDH) assay was performed to measure
cytoplasm enzyme LDH released in the extracellular medium.
Briefly, 4.0 3 103 cells were seeded in 96-well plates. LDH titers
of fibroblast and myofibroblast cultures were assessed in the
presence and absence of HGF conditions. After 24 hours, the
supernatants were collected from each well. Cell monolayer
was then treated with a cell lysis solution for 30 minutes at
room temperature. Cell lysate and supernatant were collected.
LDH activity in samples was measured using a toxicology assay
kit (TOX7; Sigma-Aldrich Corp., St. Louis, MO, USA) following
the manufacturer’s instructions. The absorbance was determined at 490 nm, and LDH activity was expressed in
international units per milliliter.

Statistical Analysis
Quantification studies were performed using Student’s t-test, 1way and 2-way ANOVA followed by Bonferroni multiple
comparisons test, or the Wilcoxon rank sum test and/or
Tukey’s multiple comparison tests. The results are expressed as
mean 6 standard error of the mean (SEM). P values < 0.05 are
considered to be statistically significant.

RESULTS
Effects of BMP7þHGF on Corneal Fibrosis and
Corneal Transparency
PEI2-GNP–mediated BMP7 and HGF gene therapy targeted to
the corneal stroma significantly dissipated preexisting
corneal fibrosis and restored corneal transparency in vivo
(Figs. 1A–J). The corneas of all rabbits were transparent
before injury (Figs. 1A, 1F) and developed dense scar/fibrosis
24 hours after alkali wound (Figs. 1B, 1G), and gene transfer
was administered at this time. Rabbit corneas that received
BMP7þHGF genes (þtherapy group) not only demonstrated a
marked reduction in corneal fibrosis but also concurrent
increased transparency on day 7 (Fig. 1H), day 14 (Fig. 1I),
and day 21 (Fig. 1J) as compared to the corneas that received
naked vector (therapy group; Figs. 1C, 1D, 1E).
Figure 2 depicts quantitative corneal clinical haze scores,
based on Fantes scoring, assigned by three independent
observers (SG, MK, AS) masked to the treatment group after
alkali wound at days 1, 7, 14, and 21. On days 14 and 21,
corneas that received PEI2-GNP–mediated BMP7þHGF therapy
showed markedly lower corneal haze scores as compared to
BSS-treated corneas. The BMP7þHGF gene delivery rendered a
statistically significant decrease in corneal fibrosis at day 14
(2.3-fold; P < 0.01) and day 21 (5.5-fold; P < 0.001) as
compared to the corresponding naked vector–delivered
control corneas. As expected, no significant difference in
corneal haze scores was observed in the þtherapy and
therapy groups on day 1 and day 7. The comparison of the
þtherapy versus naive eyes at day 1, 7, and 14 showed
significant corneal haze, but not at day 21 (P ¼ 0.215).

BMP7þHGF Gene Therapy for Corneal Fibrosis
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FIGURE 1. Biomicroscopy images before and after alkali-induced corneal injury of rabbit eyes that did not receive BMP7þHGF treatment (A–E) and
those that received BMP7þHGF treatment (F–J). Dense corneal opacity developed by day 1 after induction of alkali injury (B, G). On day 14 and day
21 post injury, corneas that received PEI2-GNP–mediated BMP7þHGF eyes showed a significant reduction of opacification (H–J) as compared to the
level of opacification in corneas that received naked vector (C–E). Scale bar: 2 mm.

Effects of BMP7þHGF on Healing of the Corneal
Stroma and Epithelium
BMP7þHGF overexpression prevented excessive scarring in
corneal stroma, and normal physiological healing was observed. Figures 3A and 3B show representative slit-lamp
biomicroscopy images on day 21 in the therapy and þtherapy
groups. A significant reduction in corneal haze and fibrosis was
observed at day 21 in corneas that received PEI2-GNP–
mediated BMP7þHGF (Fig. 3B) as compared to corneas that
received PEI2-GNP-naked plasmid (Fig. 3A). Haze scores were
0.6 versus 3.3 (P < 0.001) in the þtherapy and therapy
groups, respectively. Moreover, at day 21 subjective ocular
examination of rabbit eyes in the BMP7þHGF group appeared
normal in contrast to the eyes of the vector-only group, which
showed mild edema, inflammation, redness, and discharge.
Fluorescein staining revealed that BMP7þHGF gene transfer
is not detrimental to re-epithelization of the injured corneas
(Fig. 4). Fluorescence stereo biomicroscopy images showed
corneal ulceration and epithelial defect on day 1 after alkali
injury (Figs. 4A, 4C), but by day 21 all of the treated rabbits

FIGURE 2. Quantification of corneal opacity using the Fantes score in
the three groups of rabbits: no corneal injury group (naive; gray bar),
PEI2-GNP-naked plasmid group (therapy; black bar), and PEI2-GNP–
BMP7þHGF group (þtherapy; white bar). The graph depicts comparative haze scores 24 hours post injury and at days 7, 14, and 21 post
injury (*P < 0.01 and **P < 0.001).

demonstrated complete corneal re-epithelialization and negative fluorescein staining (Figs. 4B, 4D). The lacrimal lake, as
observed on tear strips, appeared similar in both PEI2-GNPnaked vector and BMP7þHGF groups, suggesting that combination therapy with BMP7þHGF does not compromise tear
production or invoke a dry eye condition.

Myofibroblast and Profibrotic Gene Expression
Determination of myofibroblast after alkali-induced corneal
injury indicates that BMP7þHGF gene therapy has an
inhibitory effect on myofibroblast formation and profibrotic
gene expression (Fig. 5). Immunohistologic staining of a-SMA,
a marker for myofibroblasts, demonstrated a clinically relevant
and statistically significant reduction in a-SMA-positive cells in
corneas that received BMP7þHGF genes (Fig. 5B) as compared
to corneas of the naive and PEI2-GNP-naked plasmids (Fig. 5A).
The immunofluorescence quantification graph (Fig. 5C)
showed an 83% reduction of a-SMA-positive cells (P < 0.001)
in the þtherapy group as compared to the number of a-SMApositive cells in the therapy group (Fig. 5C).
Since BMP7þHGF gene delivery into fibrotic rabbit corneas
led to a quantifiable improvement in wound healing after alkali
burn in our in vivo model, the expression of five prominent
genes (a-SMA, fibronectin, collagen I, collagen III, and collagen
IV) involved in fibrosis pathways was also examined in the
corneas of rabbits that received BSS, PEI2-GNP-naked plasmid
or BMP7þHGF genes (Fig. 6). As Figure 6 illustrates, alkali
injury significantly increased levels of the five tested profibrotic genes in the therapy corneas compared to naive
corneas from 2.2- to 5.2-fold (P < 0.001), whereas BMP7þHGF
gene transfer significantly reduced profibrotic gene expression
of the a-SMA, a 3.2-fold reduction (Fig. 6A; P <0.01);
fibronectin, a 2.3-fold reduction (Fig. 6B; P <0.01); collagen
I, a 2.1-fold reduction (Fig. 6C; P <0.01); collagen III, a 1.6-fold
reduction (Fig. 6C; P <0.01), and collagen IV, a 1.9-fold
reduction (Fig. 6C; P <0.01).

BMP7þHGF Dissipates Myofibroblasts via
Apoptosis
Double immunofluorescence staining of corneal tissue sections
for a-SMA (a myofibroblast marker) and TUNEL (an apoptosis
marker) demonstrated that HGF delivery dissipates myofibroblasts through apoptosis in the fibrotic cornea. Figure 7 shows
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FIGURE 3. Slit-lamp images at day 21 after administration of PEI2-GNP only (A) and of PEI2-GNP–mediated BMP7þHGF (B), showing persistence of
haze in the therapy eye and a clear cornea after BMP7þHGF. Scale bar: 2 mm.

FIGURE 4. Stereo fluorescence microscopy images on days 1 and 21 post injury of eyes treated with PEI2-GNP alone (A, B) or BMP7þHGF (C, D),
showing that therapy does not affect reepithelialization of the injured corneas. Scale bar: 2 mm.

FIGURE 5. Immunofluorescence images showing stromal expression of a-SMA, a myofibroblast marker, in corneas 21 days post injury in rabbits that
did not receive gene therapy (A) and those that received BMP7þHGF gene therapy (B). Quantification graph depicts the significant reduction of aSMA in the þtherapy group compared to the therapy group (P < 0.001). Scale bar: 100 lm.
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FIGURE 6. Bar graphs showing differential mRNA expression of (A) a-SMA, (B) fibronectin (FN), and (C) collagen I (Col I), collagen III (Col III), and
collagen IV (Col IV) in the corneal tissue from rabbits in the naive, PEI2-GNP (therapy), and BMP7þHGF (þtherapy) groups. Tissue was obtained 21
days after injury. BMP7þHGF treatment reduced fibrotic gene expression in injured cornea. Quantification of mRNA expression of fibrotic-related
genes by real-time PCR. Graphs depict relative fold expression of a-SMA, fibronectin, collagen I, collagen III, and collagen IV (n ¼ 6 for each group).
Error bars represent 6 SEM (**P < 0.001 against naive control and *P < 0.01 against BMP7þHGF group, respectively).

representative images of double immunofluorescence performed in corneal tissue collected on day 21 after injury. The
anterior stromal tissue of BMP7þHGF-treated corneas was
found to contain several double-stained a-SMA-positive and
TUNEL-positive cells (4.7 6 1.2/4003) and single-stained aSMA cells (4.5 6 1.1/4003) and TUNEL-positive cells (21.4 6
5.7/4003) (Fig. 7B). In contrast, the anterior stromal tissue of
corneas that received PEI2-GNP-naked vector showed only aSMA-positive cells (41.7 6 6.1/4003) (Fig. 7A). The difference
between the þtherapy and the therapy group in the
disappearance of myofibroblast via apoptosis was statistically
significant (P < 0.001).

Number of Gene Copies Driving Therapeutic
Response
Real-time PCR quantification of the number of therapeutic
gene copies responsible for reducing corneal fibrosis indicated
that sufficient delivery of the genes was achieved with the
PEI2-GNPs administered via cloning cylinder technique (Figs.
8A, 8B). Gene delivery by the PEI2-GNPs was significant, as 4.3
3 104 6 0.2 copies of BMP7 per 1 lg DNA (Fig. 8A) and 3.2 3
104 6 0.4 copies of HGF per 1 lg DNA (Fig. 8B) were detected
in treated corneas.

FIGURE 7. Double immunofluorescence staining for a-SMA and TUNEL in tissue from injured corneas treated with (A) PEI2-GNP alone (therapy)
and (B) PEI2-GN–delivered BMP7þHGF (þtherapy). Arrows point to a-SMA; arrowheads point to colocalization of a-SMA-positive and TUNELpositive cells; and arrowheads with inside tail point to TUNEL-positive cells. Scale bar: 25 lm.
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FIGURE 8. Bar graph of quantitative PCR analysis showing BMP7 (A) and HGF (B) gene copy numbers delivered by PEI2-GNPs to the rabbit cornea,
indicating efficient delivery of genes by the customized nanoparticles. There were six samples in each group and error bars represent 6 SEM (*P <
0.001 against naive control and therapy group).

In Vivo Toxicity and Safety Studies
The results of time-dependent ocular irritation studies performed in live rabbits using the Draize and modified
MacDonald-Shadduck scoring systems are highlighted in the
Table. As expected, an alkali wound led to a significantly
increased cumulative Draize score in the PEI2-GNP-naked
vector and PEI2–mediated BMP7þHGF group as compared to
naive corneas. On day 7, the average Draize score was 45.0 in
the therapy group versus 0 in the naive group (P < 0.001); on
day 14, 39.0 vs. 0 (P < 0.001); and on day 21, 29.8 vs. 0 (P <
0.001). BMP7þHGF therapy was associated with a significant,
time-dependent reduction in the cumulative Draize score
compared to the score in the therapy group as follows: day
7, 29.1 with BMP7þHGF vs. 45.0 with therapy (P < 0.01); day
14, 18.9 vs. 39.0 (P < 0.01); and day 21, 5.1 vs. 29.8 (P < 0.01).
The modified MacDonald-Shadduck test results showed a
similar pattern of scores following alkali wounding in PEI2GNP-naked vector and BMP7þHFG groups. Injured eyes that
received BMP7þHGF therapy exhibited significantly lower
modified MacDonald-Shadduck scores than did the eyes of
rabbits that received PEI2-GNP-naked vector (day 7: 0.9 vs. 1.8,
P < 0.05; day 14: 0.6 vs. 1.3, P < 0.01; day 21: 0.3 vs. 1.1, P <
0.001). On the subjective clinical eye examinations performed
independently by three examiners, significantly improved
overall ocular health was observed in the eyes of rabbits that
received gene therapy as compared to eyes of rabbits that
received the nanoparticles alone.
Evaluation of the effects of BMP7þHGF therapy on IOP and
tear production revealed no significant differences in the IOP

(Fig. 9; P > 0.1) and tear levels (data not shown) in the eyes of
rabbits among the three groups.
H&E staining demonstrated noteworthy morphologic alterations in corneal epithelium and stroma at day 21 post alkali
injury in the rabbits that received PEI2-GNP-naked vector (Fig.
10A), corroborating the presence of the clinical opacification
visualized with slit-lamp biomicroscopy. BMP7þHGF therapy
markedly mitigated the adverse impact of alkali wounding on
corneal epithelial and stromal tissues (Fig. 10B). In addition, no
significant cellular inflammatory infiltrates were observed in
the corneas of either group, as quantified with CD11b
immunofluorescence (Figs. 10C, 10D; P > 0.1). The Masson’s
trichome staining demonstrated notably decreased collagen
deposition in the rabbit corneas that received BMP7þHGF
therapy (Fig. 10F) compared to the therapy naked vector–
delivered corneas (Fig. 10E).

Role of HGF in Apoptosis of Corneal
Myofibroblasts and Fibroblasts
The molecular function of HGF on corneal fibroblasts and
myofibroblasts was studied in an established in vitro model of
corneal fibrosis in humans. Primary stromal cultures obtained
from donor human corneas and grown in the absence of TGFb1 provided corneal fibroblasts and grown in the presence of
TGF-b1 produced corneal myofibroblasts, as demonstrated by
a-SMA staining and TUNEL staining. Recombinant HGF (rHGF)
treatment of these cultures caused significant apoptosis, as
indicated by the detection of several TUNEL-positive cells in

TABLE. Draize and Modified MacDonald-Shadduck Scoring Shows the Ocular Anomaly in Therapy and þTherapy Groups
Draize Total Score

MacDonald-Shadduck Score

Groups

Day 7

Day 14

Day 21

Day 7

Day 14

Day 21

Naive
Therapy
þTherapy

0
45.0 6 0.31
29.1 6 0.29

0
39.0 6 0.23
18.9 6 0.19

0
29.8 6 0.18
5.1 6 0.14

0
1.8 6 0.32
0.9 6 0.18

0
1.3 6 0.21
0.6 6 0.12

0
1.1 6 0.19
0.3 6 0.12

The slit-lamp and stereo biomicroscopic images were scored by three independent resident observers. The naive group did not show any ocular
anomaly during Draize and modified MacDonald-Shadduck scoring (P < 0.001 or P < 0.01 or P < 0.05 between the groups at different time points).
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FIGURE 9. BMP7þHGF therapy is well tolerated in rabbit eyes. Graph
depicts IOP of the animal groups under investigation. Error bars
represent 6 SEM and no significant difference (P > 0.1) was recorded
between the groups.

human corneal myofibroblasts (Fig. 11B) but not in HCFs (Fig.
11A).
These observations were further validated by the LDH assay,
which measures cell death by gauging LDH enzyme released by
apoptotic cells. As Figure 12 shows, LDH values were
significantly higher in rHGF-treated corneal myofibroblasts
than in vehicle-treated myofibroblasts (442 6 40 vs. 130 6 11
IU/mL; P < 0.001). With corneal fibroblasts, LDH values did
not show marked differences between rHGF-treated and the
vehicle-treated cells (123 6 8 vs. 136 6 9 IU/mL).

DISCUSSION
The pathogenesis of corneal haze from mechanical, chemical,
or surgical injury is a complex cascade of molecular signaling
events that involve a variety of fibrotic pathways and ECM
remodeling factors.3,4 These events are primarily controlled by
the TGF-b signaling pathway.34,46 Corneal wound healing
involves differentiation of dormant keratocytes to active
fibroblasts and myofibroblasts, which proliferate, secrete
ECM, and aid in wound contraction and closure.4,47,48
Continued activation of myofibroblasts in the cornea, however,
leads to aberrant collagen deposition and corneal haze and
fibrosis,3,47 making regulation of myofibroblast activation an
important therapeutic target for controlling and preventing
corneal scarring.
TGF-b signaling is regulated in numerous pathways and has
a variety of functions in tissue homeostasis. It also negatively
regulates the BMP pathways,49 making it a challenge to directly
regulate the TGF-b pathway. BMP7 negatively regulates the
TGF-b signaling processes in corneal tissue remodeling by
counteracting the epithelial mesenchymal transition pathways,
which contribute to an increase in fibrosis.17,50 We previously
demonstrated in a rabbit model the efficacy of GNP-mediated
BMP7 gene transfer in reducing corneal opacity following
injury.17 HGF is another important regulator of the woundhealing process in various tissue types51 and is reported to
function through c-Met and b1-integrin signaling pathways.23
Our research team and others have demonstrated that HGF
plays a role in corneal wound healing,22 but to our knowledge
its efficacy in promoting in vivo wound healing has never been
studied in the eye, although such an effect has been described
in models of lung,39 kidney,37 hepatic,52,53 and skin wound
healing.51

IOVS j February 2018 j Vol. 59 j No. 2 j 1053
We hypothesized that HGF gene transfer in combination
with BMP7 locally into the opaque cornea could reverse the
fibrotic events in vivo in a preclinical rabbit model of corneal
fibrosis. The results of this study demonstrate that delivery of
BMP7þHGF genes into stromal fibroblasts/keratocytes via
nanoparticle (PEI2-GNP) significantly reduced corneal opacity
by 3 weeks post injury in a preclinical rabbit model of corneal
fibrosis (Figs. 1–4). Importantly, since the BMP7þHGF therapy
was administered 1 day after injury, the findings suggest that
resolution of corneal opacity and vision restoration is
achievable even in a significantly damaged cornea in vivo.
Furthermore, administration of BMP7þHGF gene therapy was
associated with a significant reduction in a-SMA, a molecular
marker for myofibroblasts, and a concomitant decrease in
profibrotic genes (Figs. 5 and 6). To corroborate the selective
apoptosis observed in rabbit myofibroblasts was driven by
HGF, we performed in vitro studies of the effects of rHGF on
human corneal myofibroblasts and fibroblasts, which demonstrated that rHGF induces apoptosis in human corneal
myofibroblasts but not in HCFs (Figs. 11 and 12). This finding
aligns with earlier reports of HGF function in pulmonary and
liver fibrosis models, which suggests that HGF-induced
myofibroblast cell death is a key event in the healing process.53
TGF-b signaling has been shown to increase the expression of
c-Met, the receptor for HGF,54 suggesting that in a fibrotic
microenvironment the HGF activity may be more pronounced
in myofibroblasts than in quiescent stromal keratinocytes. The
c-Met receptor, a proto-oncogene, has multiple functions,
including cell survival via sequestration of the Fas receptor and
inhibition of death-domain–induced signaling.55 However, in
presence of HGF, the binding of c-Met with Fas receptors
would be dampened due to c-Met activation by phosphorylation, and the cells can then respond to Fas ligand–dependent
death signals.56 In addition, HGF also induces increased
caspase-3 activity via intracellular signaling.57 Caspase-3–
dependent cleavage of the c-Met receptor converts it into a
40-kDa proapoptotic signal.58 Therefore, the selective death of
myofibroblasts observed by HGF treatment could be the result
of a combination of three factors: increased c-Met receptors on
myofibroblasts, elevated caspase activity, and the generation of
proapoptotic c-Met fragments. HGF has also been shown in
lung fibrosis models to increase matrix metalloproteinase
expression, leading to cell death and a concomitant reduction
in ECM.39 Hence, increased matrix metalloproteinase levels
could be a mechanism to prevent corneal scar formation and
aberrant rearrangement of the ECM in the presence of HGF.
On the other hand, BMP7 is well known to antagonize the
TGF-b pathway15,17 via upregulation of the Id3 proteins59 and
Smad 7 signaling.60 Coadministration of BMP7 and HGF has
been found therapeutic in renal fibrosis and tubular nephropathy.61 Expression of profibrotic factors such as a-SMA,
fibronectin, and collagens has been shown to decrease in
response to BMP7 treatment.17 Therefore, the two therapeutic
genes, BMP7 and HGF, represent two independent pathways
for controlling corneal wound healing without scarring,
namely by regulating TGF-b signaling and by selective
apoptosis of myofibroblasts. Such a combination treatment
modality, targeting the initial signaling phase (via BMP7) and
the downstream myofibroblast apoptosis and resolution (via
HGF), can therefore have a greater potential for disease
resolution even in advanced cases of fibrosis. To the best of
our knowledge, this is a first study that demonstrates
elimination of established corneal scar and restoration of
corneal transparency in vivo by activating multiple signaling
pathways. This innovative approach is expected to lead
development of the first nonsurgical gene-based therapies to
cure preexisting corneal fibrosis/scarring without significant
adverse effects.
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FIGURE 10. Combination BMP7 and HGF gene therapy is safe and caused no adverse effects in rabbit eyes. H&E images show no alteration in
corneal morphology with PEI2-GNPs alone (A) and with BMP7þHGF gene therapy (B). CD11B immunofluorescence images 21 days after corneal
injury show no infiltration of leukocytes and inflammatory markers in the stromal layer in corneal tissue from PEI2-GNP–treated rabbits (therapy)
and from BMP7þHGF-treated rabbits (þtherapy). Masson’s trichome–stained corneal tissue images show decreased collagen expression in
BMP7þHGF-treated eyes (F) compared to the therapy given eyes (E). Scale bar: 100 and 200 lm.

FIGURE 11. Immunocytochemistry images of a-SMA staining (green) and TUNEL staining (pink) in cell cultures of HCFs (A) and myofibroblasts (B)
after rHGF treatment, demonstrating that rHGF selectively induces apoptosis of corneal myofibroblasts. Arrows point to TUNEL-positive
myofibroblast cells. Scale bar: 50 lm.
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FIGURE 12. Elevated LDH activity in cells treated with rHGF. Graph
depicting the levels of LDH measured in HCFs and myofibroblasts
treated with vehicle or rHGF. Error bars represent 6 SEM (*P < 0.001
against vehicle control in respective group).

Data from decades of clinical trials in other fibrotic
diseases,62 including renal63 and pulmonary fibrosis,64 suggest that single-targeted therapy is typically less effective in
disease resolution. In the clinical setting, patients who have
incurred a corneal injury generally have well-established
corneal haze (fibrosis) at the time of presentation to an
ophthalmologist. An efficient gene delivery method as well as
a multimodal-targeted treatment approach may offer the
potential for achieving better results than what is possible
with currently available therapies. Our study found that PEI2GNP–delivered BMP7þHGF genes remained in the injured
rabbit cornea at high copy numbers for up to 3 weeks after
instillation (Fig. 8) without concomitant adverse ocular
affects such as an increase in IOP (Fig. 9) or dry eye
conditions. Furthermore, Draize and modified MacDonaldShadduck scores (Table) indicate that ocular toxicity from
BMP7þHGF combination gene therapy is minimal. Nevertheless, the long-term effects of HGFþBMP7 therapy on stromal
collagen fibril organization and neighboring ocular tissues
remain unknown and warrant further investigation. The lack
of data on long-term effects is a limitation of the present
study, and our future studies will investigate the long-term
effects of PEI2-GNP–delivered BMP7þHGF gene therapy. In
conclusion, this study demonstrates that tissue-targeted
BMP7þHGF combination gene therapy given locally with
PEI2-GNPs 1 day after alkali damage eliminates corneal
fibrosis and restores corneal transparency in vivo by negating
TGF-b pathologic activity producing myofibroblasts and
promoting apoptosis in established myofibroblasts utilizing
multiple signaling pathways.
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